Cybersecurity firm Blue Coat Systems has decided to opt-out of an initial public offering and sell itself to software security leader Symantec for $4.65 billion.
The emergence of contrarian patent investors – bargain hunters hoping to cash in on decidedly soft market for licensing and sales – are an indication that the
In what some patent holders are hoping will be a harbinger of things to come, publicly traded IP licensing companies are enjoying an unusually strong
The use of inaccurate, prejudicial language by newspapers, business publications and technology magazines to describe patent licensing activity biases readers and courts. That is among
With traditional patent strategies under pressure to show that they are still relevant, business as usual in the IP space is no longer the same.
The eagerly sought bottom for publicly traded patent licensing companies may have been reached according to the data provided by an intellectual property index that
Of the top eleven active US patent holders, only four are American companies. But who gets the best return on their innovation rights is less
Most patent holders would agree that licensing patents for revenue has gone from bad to awful — from difficult less than a decade ago, to
A California jury has awarded pharmaceutical drug company Merck $200 million, a fraction of what it had sought, for infringement of two of its patents
While many high-tech patents are suffering from devaluation the value of some pharmaceutical patents is soaring. Merck & Co. won a legal victory over
In an information age that worships data and transparency, the trade or business secret has never been more valuable. “Secrets” is an essential guide to
While it may seem like all of the patent infringement targets are large technology companies in 2015, at least 7 of the top 10 defendants